Yu Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu Liu has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Zizhen Si
Department of Psychiatry, Zhejiang Key Laboratory of Drug Addiction and Brain Health, The Affiliated Kangning Hospital of Ningbo University, Ningbo, China
10 shared publicationsWenhua Zhou
Department of Psychiatry, Zhejiang Key Laboratory of Drug Addiction and Brain Health, The Affiliated Kangning Hospital of Ningbo University, Ningbo, China
9 shared publicationsLiyin Qian
School of Public Health, Health Science Center, Ningbo University, Ningbo 315021, China
7 shared publicationsYao Shen
School of Public Health, School of Medicine, Ningbo University, 818 Fenghua Road, Ningbo, Zhejiang 315211, PR China
7 shared publicationsYuer Ruan
Department of Psychology, Collage of Teacher Education, Ningbo University, Ningbo China
7 shared publicationsZhaoying Yu
Department of Psychiatry, Affiliated Minkang Hospital of Ningbo University (Ningbo Psychiatric Hospital)
6 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1949322
The unequal cognitive consequences of social disconnection: mechanisms, modifiers and opportunities for dementia prevention
Social isolation and loneliness are increasingly recognized as important determinants of cognitive decline and dementia risk in older adults. However, the strength and nature of these associations vary substantially across populations, cognitive outcomes, and stages of ageing. This review examines the sources of such heterogeneity by distinguishing objective social isolation from subjective loneliness and exploring their different psychological, behavioural, and biological pathways. Using a systematic multi-database search and thematic synthesis, we integrated evidence from longitudinal studies, neuroimaging research, and intervention trials to identify factors that increase vulnerability and promote resilience. The review highlights how psychosocial, behavioural, neuroendocrine, and neurostructural mechanisms contribute to differences in cognitive outcomes and discusses implications for targeted and context-sensitive interventions. Remaining challenges include measurement heterogeneity, limited causal evidence, and underrepresentation of low- and middle-income countries. Future research should prioritize harmonized assessments, stratified intervention trials, and culturally adapted implementation approaches. Early identification and prevention of social disconnection may provide greater benefits than attempts to reverse established isolation.
- 12 October 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1949322
Open AccessThe unequal cognitive consequences of social disconnection: mechanisms, modifiers and opportunities for dementia prevention
Social isolation and loneliness are increasingly recognized as important determinants of cognitive decline and dementia risk in older adults. However, the strength and nature of these associations vary substantially across populations, cognitive outcomes, and stages of ageing. This review examines the sources of such heterogeneity by distinguishing objective social isolation from subjective loneliness and exploring their different psychological, behavioural, and biological pathways. Using a systematic multi-database search and thematic synthesis, we integrated evidence from longitudinal studies, neuroimaging research, and intervention trials to identify factors that increase vulnerability and promote resilience. The review highlights how psychosocial, behavioural, neuroendocrine, and neurostructural mechanisms contribute to differences in cognitive outcomes and discusses implications for targeted and context-sensitive interventions. Remaining challenges include measurement heterogeneity, limited causal evidence, and underrepresentation of low- and middle-income countries. Future research should prioritize harmonized assessments, stratified intervention trials, and culturally adapted implementation approaches. Early identification and prevention of social disconnection may provide greater benefits than attempts to reverse established isolation.
- Open Access
- 15 June 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Methamphetamine hijacks chaperone-mediated autophagy to degrade GPX4, driving ferroptosis-precipitated cognitive decline and addictive pathogenesis
Methamphetamine (METH) addiction is associated with progressive cognitive decline and maladaptive behaviors, but the molecular mechanisms bridging proteostatic dysfunction to neural circuit degeneration remain poorly defined. We hypothesized that METH hijacks chaperone-mediated autophagy (CMA), a lysosomal quality-control pathway, to drive neurodegeneration through ferroptosis. Using chronic METH self-administration models, hippocampal neurons, and CMA-targeted approaches, we demonstrated that METH coerces CMA components (HSC70-LAMP2A) to recognize a non-canonical 124NVKFD128 degron on glutathione peroxidase 4 (GPX4), resulting in its lysosomal degradation. This CMA-dependent GPX4 depletion disrupted glutathione recycling, unleashing lethal lipid peroxidation and hippocampal ferroptosis. Critically, neuronal CMA ablation rescued spatial memory deficits and reduced compulsive drug-seeking behaviors, establishing CMA hyperactivity as a causal driver of addiction-related neuropathology. Our findings extend the oxidative stress-centric model of METH toxicity by revealing CMA as a pathological switch that converts physiological proteostasis into a self-destructive cascade. The CMA-GPX4 axis, mechanistically linking protein quality control failure, iron-dependent cell death, and behavioral dysfunction, represents a druggable target, with CMA inhibitors showing preclinical efficacy in mitigating METH-induced neuropsychiatric deterioration. By redefining addiction-associated neurodegeneration as a disorder of hijacked proteostasis, this work provides a unified framework for targeting shared mechanisms in substance use disorders and neurodegenerative diseases.
- 15 June 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Open AccessMethamphetamine hijacks chaperone-mediated autophagy to degrade GPX4, driving ferroptosis-precipitated cognitive decline and addictive pathogenesis
Methamphetamine (METH) addiction is associated with progressive cognitive decline and maladaptive behaviors, but the molecular mechanisms bridging proteostatic dysfunction to neural circuit degeneration remain poorly defined. We hypothesized that METH hijacks chaperone-mediated autophagy (CMA), a lysosomal quality-control pathway, to drive neurodegeneration through ferroptosis. Using chronic METH self-administration models, hippocampal neurons, and CMA-targeted approaches, we demonstrated that METH coerces CMA components (HSC70-LAMP2A) to recognize a non-canonical 124NVKFD128 degron on glutathione peroxidase 4 (GPX4), resulting in its lysosomal degradation. This CMA-dependent GPX4 depletion disrupted glutathione recycling, unleashing lethal lipid peroxidation and hippocampal ferroptosis. Critically, neuronal CMA ablation rescued spatial memory deficits and reduced compulsive drug-seeking behaviors, establishing CMA hyperactivity as a causal driver of addiction-related neuropathology. Our findings extend the oxidative stress-centric model of METH toxicity by revealing CMA as a pathological switch that converts physiological proteostasis into a self-destructive cascade. The CMA-GPX4 axis, mechanistically linking protein quality control failure, iron-dependent cell death, and behavioral dysfunction, represents a druggable target, with CMA inhibitors showing preclinical efficacy in mitigating METH-induced neuropsychiatric deterioration. By redefining addiction-associated neurodegeneration as a disorder of hijacked proteostasis, this work provides a unified framework for targeting shared mechanisms in substance use disorders and neurodegenerative diseases.
- Open Access
- 14 April 2026
- Published by Wiley in Addiction Biology
- Vol. 31 (4) , e70152
AT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction
Although the angiotensin II type 1 receptor (AT1R), a pivotal component of the renin–angiotensin system (RAS), is associated with cardiovascular and renal homeostasis, burgeoning evidence implicates its critical role in neuropsychiatric disorders, particularly addiction. Beyond regulating haemodynamics, AT1R activation in the central nervous system (CNS) modulates neuroinflammatory cascades, dopaminergic signalling plasticity, and stress‐responsive neural circuit processes central to addiction pathophysiology. Notably, preclinical studies reveal that AT1R blockade attenuates drug‐seeking behaviours by normalizing mesolimbic dopamine dysregulation and reducing glutamatergic excitotoxicity in the nucleus accumbens. This review systematically integrates contemporary evidence elucidating the dual pathophysiological roles of AT1R in CNS disorders, with particular emphasis on neurodegenerative diseases and psychiatric conditions. Crucially, we delineate two mechanistically distinct yet interconnected functions of AT1R: (1) serving as a critical mediator of maladaptive neuroplasticity during protracted exposure to addictive substances and (2) functioning as a regulator of blood–brain barrier (BBB) integrity, thereby potentiating neurotoxicant infiltration in substance use disorders. Building upon these mechanistic insights, we propose a translational framework for repurposing clinically approved AT1R antagonists as novel pharmacotherapies targeting addiction‐related neurocircuitry dysregulation. By bridging molecular insights with translational opportunities, this work positions AT1R as a novel therapeutic target to address unmet clinical needs in addiction.
- 14 April 2026
- Published by Wiley in Addiction Biology
- Vol. 31 (4) , e70152
Open AccessAT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction
Although the angiotensin II type 1 receptor (AT1R), a pivotal component of the renin–angiotensin system (RAS), is associated with cardiovascular and renal homeostasis, burgeoning evidence implicates its critical role in neuropsychiatric disorders, particularly addiction. Beyond regulating haemodynamics, AT1R activation in the central nervous system (CNS) modulates neuroinflammatory cascades, dopaminergic signalling plasticity, and stress‐responsive neural circuit processes central to addiction pathophysiology. Notably, preclinical studies reveal that AT1R blockade attenuates drug‐seeking behaviours by normalizing mesolimbic dopamine dysregulation and reducing glutamatergic excitotoxicity in the nucleus accumbens. This review systematically integrates contemporary evidence elucidating the dual pathophysiological roles of AT1R in CNS disorders, with particular emphasis on neurodegenerative diseases and psychiatric conditions. Crucially, we delineate two mechanistically distinct yet interconnected functions of AT1R: (1) serving as a critical mediator of maladaptive neuroplasticity during protracted exposure to addictive substances and (2) functioning as a regulator of blood–brain barrier (BBB) integrity, thereby potentiating neurotoxicant infiltration in substance use disorders. Building upon these mechanistic insights, we propose a translational framework for repurposing clinically approved AT1R antagonists as novel pharmacotherapies targeting addiction‐related neurocircuitry dysregulation. By bridging molecular insights with translational opportunities, this work positions AT1R as a novel therapeutic target to address unmet clinical needs in addiction.
- Open Access
- 22 December 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1)
Propofol addiction drives neuronal senescence and cognitive decline via autophagy-mediated ADAR1/SIRT1 disruption
Propofol addiction represents a significant clinical challenge with no approved pharmacotherapy. While cognitive decline is a hallmark of substance use disorders, its underlying mechanisms in propofol addiction remain unclear. This study investigates whether propofol abuse induces neuronal senescence and cognitive impairment and explores the involved molecular pathways. We found that propofol administration in mice led to significant learning and memory deficits, which were associated with p16 INK4a -dependent neuronal senescence in the hippocampus. Knockdown of p16 INK4a alleviated both senescence and cognitive decline. Mechanistically, propofol triggered autophagic degradation of ADAR1 via LC3-binding motifs, leading to reduced SIRT1 expression and subsequent upregulation of p16 INK4a . Both neuronal-specific and systemic inhibition of autophagy attenuated propofol-induced senescence, cognitive impairment, and addictive behaviors. Our findings reveal a novel ADAR1-SIRT1- p16 INK4a pathway mediated by autophagy in propofol addiction, suggesting that targeting autophagy or senescence may offer therapeutic strategies for treating propofol use disorder.
- 22 December 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1)
Open AccessPropofol addiction drives neuronal senescence and cognitive decline via autophagy-mediated ADAR1/SIRT1 disruption
Propofol addiction represents a significant clinical challenge with no approved pharmacotherapy. While cognitive decline is a hallmark of substance use disorders, its underlying mechanisms in propofol addiction remain unclear. This study investigates whether propofol abuse induces neuronal senescence and cognitive impairment and explores the involved molecular pathways. We found that propofol administration in mice led to significant learning and memory deficits, which were associated with p16 INK4a -dependent neuronal senescence in the hippocampus. Knockdown of p16 INK4a alleviated both senescence and cognitive decline. Mechanistically, propofol triggered autophagic degradation of ADAR1 via LC3-binding motifs, leading to reduced SIRT1 expression and subsequent upregulation of p16 INK4a . Both neuronal-specific and systemic inhibition of autophagy attenuated propofol-induced senescence, cognitive impairment, and addictive behaviors. Our findings reveal a novel ADAR1-SIRT1- p16 INK4a pathway mediated by autophagy in propofol addiction, suggesting that targeting autophagy or senescence may offer therapeutic strategies for treating propofol use disorder.
- Retraction
- 2 September 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 275, 112857
Retraction notice to “The effect of the NLRP1 inflammasome on methamphetamine-induced cognitive impairment in rats” [Drug and Alcohol Dependence 237 (2022) 109537]
- 2 September 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 275, 112857
RetractionRetraction notice to “The effect of the NLRP1 inflammasome on methamphetamine-induced cognitive impairment in rats” [Drug and Alcohol Dependence 237 (2022) 109537]
- Open Access
- 8 July 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (7) , 1016
Effects of Angiotensin II Receptor 1 Inhibition by LCZ696 on the Acquisition and Relapse of Methamphetamine-Associated Contextual Memory
Background/Objectives: Contextual memory associated with methamphetamine (METH) use contributes to relapse and persistence of addiction. Angiotensin II type 1 receptor (AT1R) signaling has been implicated in drug reinforcement. LCZ696, a clinically used combination of sacubitril (a neprilysin inhibitor) and valsartan (an AT1R antagonist), may interfere with METH-associated memory through the modulation of dopaminergic pathways. Methods: Male C57BL/6J mice were tested in a conditioned place preference (CPP) paradigm to assess the effects of LCZ696, sacubitril (AHU377), and valsartan on METH-induced memory expression and reinstatement. Synaptic plasticity in the nucleus accumbens (NAc) was examined by assessing the levels of synaptophysin (Syp) and postsynaptic density protein 95 (Psd95), as well as dendritic spine density. Dopaminergic signaling in the ventral tegmental area (VTA) was evaluated via ELISA, Western blotting, and chromatin immunoprecipitation (ChIP), targeting cAMP response element-binding protein (Creb) binding to the tyrosine hydroxylase (Th) promoter. To further assess the role of Th, an adeno-associated virus (AAV9) carrying a CRISPR-Cas9-based sgRNA targeting Th (AAV9-Th-sgRNA) was microinjected into the VTA. Results: LCZ696 and valsartan significantly reduced METH-induced CPP and reinstatement. LCZ696 reversed METH-induced synaptic and dopaminergic alterations and suppressed Creb-mediated Th transcription. Th knockdown attenuated both CPP acquisition and relapse. Conclusions: LCZ696 disrupts METH-associated contextual memory by modulating dopaminergic signaling and Creb-dependent Th expression, supporting its potential as a treatment for METH use disorder.
- 8 July 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (7) , 1016
Open AccessEffects of Angiotensin II Receptor 1 Inhibition by LCZ696 on the Acquisition and Relapse of Methamphetamine-Associated Contextual Memory
Background/Objectives: Contextual memory associated with methamphetamine (METH) use contributes to relapse and persistence of addiction. Angiotensin II type 1 receptor (AT1R) signaling has been implicated in drug reinforcement. LCZ696, a clinically used combination of sacubitril (a neprilysin inhibitor) and valsartan (an AT1R antagonist), may interfere with METH-associated memory through the modulation of dopaminergic pathways. Methods: Male C57BL/6J mice were tested in a conditioned place preference (CPP) paradigm to assess the effects of LCZ696, sacubitril (AHU377), and valsartan on METH-induced memory expression and reinstatement. Synaptic plasticity in the nucleus accumbens (NAc) was examined by assessing the levels of synaptophysin (Syp) and postsynaptic density protein 95 (Psd95), as well as dendritic spine density. Dopaminergic signaling in the ventral tegmental area (VTA) was evaluated via ELISA, Western blotting, and chromatin immunoprecipitation (ChIP), targeting cAMP response element-binding protein (Creb) binding to the tyrosine hydroxylase (Th) promoter. To further assess the role of Th, an adeno-associated virus (AAV9) carrying a CRISPR-Cas9-based sgRNA targeting Th (AAV9-Th-sgRNA) was microinjected into the VTA. Results: LCZ696 and valsartan significantly reduced METH-induced CPP and reinstatement. LCZ696 reversed METH-induced synaptic and dopaminergic alterations and suppressed Creb-mediated Th transcription. Th knockdown attenuated both CPP acquisition and relapse. Conclusions: LCZ696 disrupts METH-associated contextual memory by modulating dopaminergic signaling and Creb-dependent Th expression, supporting its potential as a treatment for METH use disorder.
- 20 November 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (1) , 1-15
The effect of paeoniflorin on the rewarding effect of methamphetamine and the associated cognitive impairment in mice
Chronic exposure to methamphetamine (METH) has been suggested to cause METH use disorder and severe cognitive impairment. Paeoniflorin (PF) is a monoterpenoid glycoside with various beneficial effects, including anti-inflammatory, antioxidant and antidepressant. The current study was designed to investigate the effect of PF (30 mg/kg, i.p.) on the rewarding effect of METH (2.5 mg/kg, i.p.) and the associated cognitive impairment, using the animal model of conditioned place preference, new location reorganization test, new object reorganization test and Y-maze test. METH induced conditioned place preference, accompanied by increased expression of synapse-associated proteins in the ventral target areas (VTA) and nucleus accumbens (NAc). In addition, METH induced significant cognitive impairment and decreased the expression of synapse-associated proteins in the hippocampus (Hip). Administration of PF decreased the rewarding effect of METH and the expression of synapse-associated proteins in the VTA or NAc. PF was also effective to improve METH-induced cognitive impairment by upregulating the expression of synapse-associated proteins in the Hip. Therefore, PF could be a potential agent for the treatment of METH use disorder and the associated cognitive impairment.
- 20 November 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (1) , 1-15
The effect of paeoniflorin on the rewarding effect of methamphetamine and the associated cognitive impairment in mice
Chronic exposure to methamphetamine (METH) has been suggested to cause METH use disorder and severe cognitive impairment. Paeoniflorin (PF) is a monoterpenoid glycoside with various beneficial effects, including anti-inflammatory, antioxidant and antidepressant. The current study was designed to investigate the effect of PF (30 mg/kg, i.p.) on the rewarding effect of METH (2.5 mg/kg, i.p.) and the associated cognitive impairment, using the animal model of conditioned place preference, new location reorganization test, new object reorganization test and Y-maze test. METH induced conditioned place preference, accompanied by increased expression of synapse-associated proteins in the ventral target areas (VTA) and nucleus accumbens (NAc). In addition, METH induced significant cognitive impairment and decreased the expression of synapse-associated proteins in the hippocampus (Hip). Administration of PF decreased the rewarding effect of METH and the expression of synapse-associated proteins in the VTA or NAc. PF was also effective to improve METH-induced cognitive impairment by upregulating the expression of synapse-associated proteins in the Hip. Therefore, PF could be a potential agent for the treatment of METH use disorder and the associated cognitive impairment.
- 30 July 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 981, 176866
The role of heterodimers formed by histamine H3 receptors and dopamine D1 receptors on the methamphetamine-induced conditioned place preference
- 30 July 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 981, 176866
The role of heterodimers formed by histamine H3 receptors and dopamine D1 receptors on the methamphetamine-induced conditioned place preference
- 2 June 2024
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 120, 167-180
Inhibition of GSDMD-dependent pyroptosis decreased methamphetamine self-administration in rats
- 2 June 2024
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 120, 167-180
Inhibition of GSDMD-dependent pyroptosis decreased methamphetamine self-administration in rats